PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
PARP inhibitors have shown promising clinical activities for patients with BRCA mutations and are changing the landscape of ovarian cancer treatment. However, the therapeutic mechanisms of action for PARP inhibition in the interaction of tumors with the tumor microenvironment and the host immune sys...
Saved in:
Published in | Cell reports (Cambridge) Vol. 25; no. 11; pp. 2972 - 2980.e5 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
11.12.2018
Elsevier |
Subjects | |
Online Access | Get full text |
ISSN | 2211-1247 2211-1247 |
DOI | 10.1016/j.celrep.2018.11.054 |
Cover
Loading…
Summary: | PARP inhibitors have shown promising clinical activities for patients with BRCA mutations and are changing the landscape of ovarian cancer treatment. However, the therapeutic mechanisms of action for PARP inhibition in the interaction of tumors with the tumor microenvironment and the host immune system remain unclear. We find that PARP inhibition by olaparib triggers robust local and systemic antitumor immunity involving both adaptive and innate immune responses through a STING-dependent antitumor immune response in mice bearing Brca1-deficient ovarian tumors. This effect is further augmented when olaparib is combined with PD-1 blockade. Our findings thus provide a molecular mechanism underlying antitumor activity by PARP inhibition and lay a foundation to improve therapeutic outcome for cancer patients.
[Display omitted]
•T cell-mediated cytotoxicity is important for therapeutic activity of PARP inhibition•Olaparib-treated Brca1-deficient tumor cells activate the STING pathway in APCs•STING pathway activation is required for the antitumor efficacy of PARP inhibition•PD-1 blockade enhances the antitumor efficacy of olaparib in Brca1-deficient tumors
Ding et al. show that PARP inhibition in Brca1-deficient tumors elicits strong antitumor immunity involving activation of both innate and adaptive immune responses, a process that is dependent on STING pathway activation. In addition, they show that addition of PD-1 blockade augments the therapeutic efficacy of PARP inhibitor treatment. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 L.D., H.-J.K., Q.W., P.A.K., U.A.M., and J.J.Z. designed the study. L.D., H.-J.K., and Q.W. performed the experiments. L.D., H.-J.K., Q.W., and J.J.Z. analyzed data. C.E.O., T.J., and M.K. helped with mouse model generation and in vivo treatment. S.L. helped with the flow cytometry analysis. B.E.H. and R.T.B. performed histological analysis. B.B.L. performed the GSEA analyses. J.F.L., E.H.S., B.B.L., P.A.K., T.M.R., and G.J.F. contributed to scientific discussions. L.D., H.-J.K., Q.W., B.B.L., G.J.F., P.A.K., U.A.M., and J.J.Z. wrote and reviewed the manuscript. AUTHOR CONTRIBUTIONS |
ISSN: | 2211-1247 2211-1247 |
DOI: | 10.1016/j.celrep.2018.11.054 |